In:
Diabetes, Obesity and Metabolism, Wiley, Vol. 20, No. 11 ( 2018-11), p. 2685-2689
Kurzfassung:
We investigated the short‐term effects of dapagliflozin as adjunct to insulin on insulin sensitivity, postprandial glucose excursions and ketone body production in type 1 diabetes mellitus (T1DM). A total of seven male patients completed the randomized, double‐blind, placebo‐controlled cross‐over trial, receiving 10 mg of dapagliflozin daily for 3 days, followed by placebo, or the reverse. At Day 3, hyperinsulinaemic, euglycaemic clamps and oral glucose tolerance test clamps with repeated blood sampling were performed. Required glucose infusion and blood glucose excursions did not differ significantly between dapagliflozin treatment and placebo ( P = 0.491; P = 0.342). Prior to oral glucose, total ketone bodies showed a higher trend following dapagliflozin treatment ( P = 0.051). Following oral glucose, total ketone bodies decreased while concentrations of total GLP‐1 were higher following dapagliflozin ( P = 0.009). Non‐esterified free fatty acids did not differ between dapagliflozin treatment and placebo and ketonuria was absent under both conditions. In T1DM, short‐term addition of dapagliflozin to insulin influenced neither postprandial glucose excursions nor insulin sensitivity. Following oral glucose, total ketone bodies decreased in parallel with an increase in GLP‐1 concentrations, which were higher under dapagliflozin treatment as compared with placebo.
Materialart:
Online-Ressource
ISSN:
1462-8902
,
1463-1326
DOI:
10.1111/dom.2018.20.issue-11
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2018
ZDB Id:
2004918-3
